The market for needle-free drug delivery devices is projected to expand significantly, growing from US$ 14.76 million in 2023 to an impressive US$ 2842 million by 2031, with a compound annual growth rate (CAGR) of 8.5% anticipated from 2024 to 2031.

Needle-free drug delivery systems encompass various forms such as power sprays, jet injectors, inhalers, and transdermal patches. These innovative technologies alleviate patient anxiety associated with needle use. Needle-free devices provide effective administration for a broad spectrum of medications and are considered bioequivalent to traditional needle-based methods. The advantages of these devices include reduced pain during administration, rapid delivery, elimination of needle disposal concerns, and the potential for self-administration. Consequently, the numerous benefits of needle-free drug delivery systems compared to conventional needles and syringes are driving the rising demand in this market.

The increasing prevalence of chronic illnesses and lifestyle-related disorders is a significant factor propelling the growth of the needle-free drug delivery device market.

Chronic conditions such as heart disease, diabetes, and cancer rank among the top causes of mortality and disability globally. According to the Centers for Disease Control and Prevention (CDC), approximately 38.4 million individuals in the United States were diagnosed with diabetes in 2021. To manage diabetes effectively, insulin must be administered through the subcutaneous layer at regular intervals. As diabetes rates continue to rise, so does the demand for insulin delivery methods. A comprehensive multinational study published in 2021, titled "Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study," revealed that around 40% of 73,076 adults surveyed across 33 countries experienced functional gastrointestinal disorders (FGIDs). These issues are particularly prevalent among the elderly population, especially those aged 64 and older. A 2022 study, "Gastrointestinal Problems Among Indian Adults: Evidence from Longitudinal Aging Study in India," reported a self-reported prevalence of gastrointestinal disorders at approximately 18%. This study also highlighted varying rates of gastrointestinal issues globally, ranging from 14% in Iran to as high as 54% in certain Western nations. Cardiovascular diseases (CVDs), particularly those linked to modern lifestyles, are a major contributor to global mortality rates. The International Diabetes Federation (IDF) reported that in 2021, 537 million individuals aged 20-79 were living with diabetes, with projections suggesting this number could rise to 783 million by 2045. Furthermore, diabetes was responsible for 6.7 million deaths worldwide in 2021. The Neurological Alliance noted that around 14.7 million neurological cases were documented in 2019, indicating that at least one in six individuals suffers from one or more neurological conditions. The escalating prevalence of chronic diseases and the growing need for various needle-free drug delivery systems are significantly driving market expansion.

Geographically, the needle-free drug delivery device market is divided into several regions: North America (including the US, Canada, and Mexico), Europe (comprising the UK, Germany, France, Italy, Spain, and other European nations), Asia Pacific (including China, Japan, India, South Korea, Australia, and the rest of the Asia Pacific region), the Middle East & Africa (covering the UAE, Saudi Arabia, South Africa, and other countries in the region), and South & Central America (including Brazil, Argentina, and other nations in the region). North America stands out as the largest contributor to the global growth of the needle-free drug delivery device market. The Asia Pacific region is expected to exhibit the highest CAGR during the period from 2024 to 2031. In 2023, North America led the market for needle-free drug delivery devices, driven by a surge in demand for medications targeting rare diseases from biopharmaceutical and biotechnology firms, the presence of major market players, an increase in product launches, a rise in needle stick injury incidents, and extensive research and development efforts by academic institutions, pharmaceutical companies, and biotechnology firms.

Key primary and secondary sources utilized in the preparation of the report on the needle-free drug delivery device market include the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the National Library of Medicine (NLM).